Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHL TelemedicineSHMLF 52 EV-to-EBITDA is -5.84 as of Jul. 20, 2026. GuruFocus rates SHMLF with a GF Score™ of 52/100 and a GF Value™ of $12.26. The stock has 3 warning signs investors should review. Among 506 Healthcare Providers & Services companies, SHL Telemedicine ranks worse than 197628.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SHL Telemedicine's enterprise value is $35.21 Mil.
SHL Telemedicine's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.03 Mil. Therefore, SHL Telemedicine's EV-to-EBITDA for today is -5.84.
The historical rank and industry rank for SHL Telemedicine's EV-to-EBITDA or its related term are showing as below:
SHMLF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.29 Med: 8.82 Max: 79.68
Current: -5.93
During the past 13 years, the highest EV-to-EBITDA of SHL Telemedicine was 79.68. The lowest was -39.29. And the median was 8.82.
SHMLF's EV-to-EBITDA is ranked worse than 100% of 506
companies
in the Healthcare Providers & Services industry
Industry Median: 11.1
vs SHMLF: -5.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SHL Telemedicine's PE Ratio (TTM) for today is calculated as:
SHL Telemedicine's share price for today is $4.84385.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SHL Telemedicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.721.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for SHL Telemedicine's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, SHL Telemedicine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's EV-to-EBITDA falls into.
SHL Telemedicine's current Enterprise Value is $35.21 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SHL Telemedicine's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHL Telemedicine (SHMLF) has a EV-to-EBITDA of -5.84 as of Jul. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SHL Telemedicine. According to the industry distribution chart, SHL Telemedicine ranks #999999 out of 506 companies in the Healthcare Providers & Services industry.
Is SHL Telemedicine's EV-to-EBITDA too high?
SHL Telemedicine's current EV-to-EBITDA is -5.84. Based on the distribution chart, SHL Telemedicine ranks #999999 out of 506 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, SHL Telemedicine has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #999999 out of 506 companies for EV-to-EBITDA. This places SHL Telemedicine in the lower half of its industry. The industry median EV-to-EBITDA is 11.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.10, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SHL Telemedicine. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current EV-to-EBITDA is -5.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current EV-to-EBITDA of -5.84. The stock's GF Value™ is $12.26, compared to a current price of $4.84 — trading 60.5% below its estimated fair value. The current EV-to-EBITDA is -5.84. SHL Telemedicine's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current EV-to-EBITDA is -5.84 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (SHMLF) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of $4.84 is trading 60.5% below its estimated GF Value™ of $12.26.
Key valuation signals for SHMLF:
EV-to-EBITDA: -5.84
GF Value™: $12.26 vs. price of $4.84 (60.5% below fair value)
No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
52GF Score
Get the complete analysis for SHMLF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHMLF has been successfully added to your 
